Barrier Therapeutics Acquires U.S. and Canadian Rights to Solage

Barrier Therapeutics, a pharmaceutical company developing products in the field of dermatology, has announced the acquisition of the U.S. and Canadian rights to Solage (mequinol 2 percent, tretinoin 0.01 percent) Topical Solution from Moreland Enterprises. Under the terms of the acquisition, Barrier made an initial cash payment of $3 million and will make future payments totaling up to an additional $2 million, depending upon future sales of the product.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=18944720&full=1)